Empower your career - a female perspective
This session is powered by TOPX Network
27 November 2025 - Ghent ICC
In this session, each panelist will share a bit about their journey,
from where they started to how they reached their current roles. After
the introductions, we’ll dive deeper into their unique career paths. Our
speakers will discuss the key lessons they've learned along the way and
offer valuable advice for women looking to follow in their footsteps.
Don’t miss this opportunity to learn from and connect with women who are
making waves in the Life Sciences!
An Van Den Bulcke | COO & Business Development | 4Tissue
An Van Den Bulcke, Ph.D. – Innovation leader in polymers, biomedical materials, and technology commercialisation. Former Senior Business Developer at Ghent University, driving biomedical research to market through industrial partnerships, IP strategy, licensing, and spin-off creation. Co-founded AVROXA (2018), delivering high-quality poly(2-oxazoline)s, and shaped BIOINX’s early business strategy (inc. 2022). Since 2023, COO and co-founder of 4TISSUE, specialising in clinical validation of novel hydrogels and tissue mimics for regenerative medicine. Lead product: minimally invasive breast reconstruction solution. Combines deep scientific expertise with strategic business execution to accelerate innovation from lab to market.
About 4Tissue
4Tissue is a pioneering biotech spin-off company from Ghent University, Ghent University Hospital, and Vrije Universiteit Brussel, pioneering regenerative medicine through bio-interactive, injectable hydrogels in regenerative medicine. 4Tissue addresses the urgent need for safer, more natural breast reconstruction after cancer treatment. Its injectable hydrogel tissue-mimic technology stimulates the body’s own cell regeneration, offering durable, predictable results without invasive implants or flap surgeries. Leveraging cutting-edge science and a multidisciplinary team, 4Tissue is reshaping reconstructive care and driving the future of tissue regeneration to improve patient outcomes worldwide.
An Van Den Bulcke | COO & Business Development | 4Tissue
An Van Den Bulcke, Ph.D. – Innovation leader in polymers, biomedical materials, and technology commercialisation. Former Senior Business Developer at Ghent University, driving biomedical research to market through industrial partnerships, IP strategy, licensing, and spin-off creation. Co-founded AVROXA (2018), delivering high-quality poly(2-oxazoline)s, and shaped BIOINX’s early business strategy (inc. 2022). Since 2023, COO and co-founder of 4TISSUE, specialising in clinical validation of novel hydrogels and tissue mimics for regenerative medicine. Lead product: minimally invasive breast reconstruction solution. Combines deep scientific expertise with strategic business execution to accelerate innovation from lab to market.
About 4Tissue
4Tissue is a pioneering biotech spin-off company from Ghent University, Ghent University Hospital, and Vrije Universiteit Brussel, pioneering regenerative medicine through bio-interactive, injectable hydrogels in regenerative medicine. 4Tissue addresses the urgent need for safer, more natural breast reconstruction after cancer treatment. Its injectable hydrogel tissue-mimic technology stimulates the body’s own cell regeneration, offering durable, predictable results without invasive implants or flap surgeries. Leveraging cutting-edge science and a multidisciplinary team, 4Tissue is reshaping reconstructive care and driving the future of tissue regeneration to improve patient outcomes worldwide.
This session is powered by:
| For job seekers | For employers | Join BCF Career Event |
| | Register BCF BE | |
| Powered by: Hyphen Projects Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 |
© Copyright 2025 by Hyphen Projects